Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications

• Sarepta Therapeutics Inc (NASDAQ: SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone promises.

• Under the agreement, Sarepta will have the rights to five neuromuscular and cardiac indications, including Duchenne muscular dystrophy.

• According to Sarepta, the deal covers the MyoAAV program that aims to deliver more efficient gene therapies and at lower doses using modified capsids.

• Also Read: Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts.

• Delivered 25-50 times greater gene expression in multiple skeletal muscles and 10-15 times greater gene expression in cardiac muscle;

• Demonstrated reduced delivery to the liver by 50% and showed lower accumulation in the liver.

• Due to increased efficiency, it can be used at up to a log lower dose than traditional AAV vectors.

• Full research for MyoAAV in a Duchenne mouse model was published in Cell in 2021. Sarepta CEO Doug Ingram said the viruses could "substantially reduce viral load," while CSO Louise Rodino-Klapac touted the platform's "broad applicability."

• Price Action: SRPT shares are up 3.17% at $109.38 during the market session on the last check Monday.

See more from Benzinga

• Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts

• Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.